6746-11-8

Basic information

• Product Name: p-[Bis(2-chloroethyl)amino]hydrocinnamic acid
• Synonyms: CB-1332;p-[Bis(2-chloroethyl)amino]hydrocinnamic acid;3-{4-[Bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid
• CAS NO: 6746-11-8
• Molecular Formula: C₁₃H₁₇Cl₂NO₂
• Molecular Weight: 290.1856
• Mol File: 6746-11-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 447°Cat760mmHg
• Flash Point: 224.1°C
• Appearance: /
• Density: 1.277g/cm³
• Vapor Pressure: 8.98E-09mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: p-[Bis(2-chloroethyl)amino]hydrocinnamic acid(CAS DataBase Reference)
• NIST Chemistry Reference: p-[Bis(2-chloroethyl)amino]hydrocinnamic acid(6746-11-8)
• EPA Substance Registry System: p-[Bis(2-chloroethyl)amino]hydrocinnamic acid(6746-11-8)

Safety Data

• Hazardous Substances Data: 6746-11-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H17Cl2NO2/c14-7-9-16(10-8-15)12-4-1-11(2-5-12)3-6-13(17)18/h1-2,4-5H,3,6-10H2,(H,17,18)

Upstream product

• 16642-79-8 3-(4-nitrophenyl)propionic acid 
• 1208-03-3 4-(bis(2-chloroethyl)amino)benzaldehyde 
• 124673-89-8 3-{4-[bis-(2-hydroxy-ethyl)-amino]-phenyl}-propionic acid ethyl ester 
• 7116-44-1 ethyl 4-aminohydrocinnamate 
• 64977-23-7 ethyl 3-[4-(N,N-bis(2-chloroethyl)amino)phenyl]propanoate 

Downstream Products

• 159277-30-2 2-(2-{4-[Bis-(2-chloro-ethyl)-amino]-phenyl}-ethyl)-3H-benzoimidazole-5-carbonitrile 
• 159277-29-9 3-(4-(N,N-bis(2-chloroethyl)amino)phenyl)propanal 
• 159277-28-8 4-(4-(N,N-bis(2-chloroethyl)amino)phenyl)propanol 

Relevant articles and documents

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

DNA-targeted alkylating agents

The invention relates to novel bis-benzimidazole compounds which have the ability to bind to the minor groove of DNA and to alkylate DNA, to methods of preparing the compounds, and the use of the compounds in the treatement of neoplastic disease.